Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 3, 2022

Primary Completion Date

January 1, 2025

Study Completion Date

November 1, 2025

Conditions

Ocular Melanoma

Interventions

DRUG

Darovasertib

Oral Darovasertib 300 mg tablets twice daily

Trial Locations (2)

Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney

Alfred Hospital, Melbourne

All Listed Sponsors

lead

St Vincent's Hospital, Sydney

OTHER